NeoGenomics Q2 FY26 adjusted EBITDA climbs 36% to $14 million; revenue rises 11% to $202 million
PUBT · 17h ago
Share
Listen to the news
- NeoGenomics posted Q2 2026 revenue of $202 million, up 11% year over year.
- Adjusted EBITDA climbed 36% to $14 million, lifting adjusted EBITDA margin 130 basis points to 7.2%.
- Operating expense fell 3% to $102 million; period-end cash totaled $146 million following $20 million of operating cash flow.
- NGS revenue rose 26% year over year on 14% higher volume; clinical volume increased 2% to 363,000 tests.
- Raised full-year 2026 revenue guidance to $802-$806 million, projecting adjusted EBITDA of $56-$58 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved